Notice of Results and Investor Presentation

RNS Number : 7341P

Sareum Holdings PLC

21 October 2021

 

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Notice of Final Results for the Year Ended 30 June 2021 and Investor Presentation

Cambridge, UK, 21 October 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, will announce its results for the year ended 30 June 2021 on Monday, 25 October 2021.

The Company will be holding a presentation to investors on Tuesday, 2 November 2021 at 11.00 a.m. via the Investor Meet Company ("IMC") platform.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00 a.m. the day before the meeting or at any time during the live presentation. Although the Company may not be able to answer every question it receives, it will seek to address the most prominent questions within the confines of information already disclosed to the market. Responses from the Q&A session will be published at the earliest opportunity on the IMC platform.

Investors can sign up to Investor Meet Company for free and add to meet SAREUM HOLDINGS PLC via:

https://www.investormeetcompany.com/loungers-plc/register-investor

Investors who already follow SAREUM HOLDINGS PLC on the Investor Meet Company platform will automatically be invited.

A copy of the presentation will be made available on the Company's website following the presentation.

For further information, please contact: 

Sareum Holdings plc Tim Mitchell, CEO	01223 497 700
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman	020 7409 3494
Hybridan LLP (Nominated Broker) Claire Noyce	020 3764 2341
MEDiSTRAVA Consulting (Financial PR) Mark Swallow / David Dible	020 7638 9571

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com  

- Ends -

 

END

 

 

NORDKKBNOBDDNKB